We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SOLB:EURONEXT BRUSSELSSolvay SA Analysis

Data as of 2026-03-12 - not real-time

€26.72

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Solvay SA (SOLB) trades just below its 20‑day simple moving average and marginally above the 50‑day average, placing the price in a neutral technical zone. The Relative Strength Index hovers around the midpoint, while a bearish MACD crossover and declining volume suggest limited upside momentum in the short run. Fundamentally, the stock carries an exceptionally high trailing P/E contrasted by a much lower forward P/E, indicating that earnings expectations are improving but the current valuation remains stretched relative to the discounted cash‑flow fair value estimate. The company offers a high double‑digit dividend yield with a very low payout ratio, supported by solid operating cash flow and free cash flow, making the dividend appear sustainable despite thin profit margins and a recent revenue decline. Market sentiment is bullish, reflected by an “Extreme Greed” reading on the fear‑greed index, yet the 30‑day volatility is elevated and the beta is remarkably low, pointing to idiosyncratic risk rather than broad market risk.
Given the modest upside to the DCF fair value, the overvalued technical positioning, and the heavy debt load, the stock is best viewed as a value play anchored by its dividend rather than a growth catalyst. Investors should weigh the attractive yield against the high valuation and operational challenges, and consider a cautious stance until price momentum aligns with the underlying fundamentals.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and decreasing volume limit upside
  • High dividend yield provides income cushion
  • Price near support level adds downside protection

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Forward earnings improvement narrows valuation gap
  • Debt burden remains a concern for credit health
  • Sector cyclicality may affect revenue recovery

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Sustainable dividend supports total return
  • Low growth outlook and high debt limit upside
  • Potential regulatory headwinds in chemicals industry

Key Metrics & Analysis

Financial Health

Revenue Growth-12.80%
Profit Margin0.63%
P/E Ratio95.4
ROE2.98%
ROA4.57%
Debt/Equity200.56
P/B Ratio2.7
Op. Cash Flow€682.0M
Free Cash Flow€336.9M

Technical Analysis

TrendNeutral
RSI50.7
Support€24.86
Resistance€29.02
MA 20€26.92
MA 50€26.67
MA 200€27.64
MACDBearish
VolumeDecreasing
Fear & Greed Index75.07

Valuation

Fair Value€28.96
Target Price€25.72
Upside/Downside-3.75%
GradeOvervalued
TypeValue
Dividend Yield9.43%

Risk Assessment

Beta0.10
Volatility31.06%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.